Caris Life Sciences, Inc. (CAI)
26.03
-7.19
(-21.64%)
USD |
NASDAQ |
Nov 05, 16:00
26.45
+0.42
(+1.61%)
After-Hours: 06:50
Caris Life Sciences SG&A Expense (TTM) : 325.72M for Sept. 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 325.72M |
| June 30, 2026 | 418.96M |
| March 31, 2026 | 405.28M |
| December 31, 2025 | 392.47M |
| September 30, 2025 | 291.82M |
| June 30, 2025 | 198.58M |
| Date | Value |
|---|---|
| March 31, 2025 | 91.95M |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Natera, Inc. | 1.255B |
| Myriad Genetics, Inc. | 401.00M |
| BioRestorative Therapies, Inc. | 5.181M |
| CareDx, Inc. | 264.45M |
| Exagen, Inc. | 48.45M |